These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29200824)

  • 1. Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules.
    Zaid AN; Zohud N; E'layan B; Aburadi T; Jaradat N; Ali I; Hussein F; Ghanem M; Qaddomi A; Abu Zaaror Y
    Drug Des Devel Ther; 2017; 11():3291-3298. PubMed ID: 29200824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions.
    Di Marco M; Marier JF; Ducharme MP; Morin I; Engel C; Gulbranson S; Thudi NR; Murpani D; Rampal A; Monif T; Koundinya TS; Deo K; Monif T
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):319-26. PubMed ID: 18541129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoemulsified orlistat-embedded multi-unit pellet system (MUPS) with improved dissolution and pancreatic lipase inhibition.
    Sangwai M; Sardar S; Vavia P
    Pharm Dev Technol; 2014 Feb; 19(1):31-41. PubMed ID: 23259606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPLC analysis of orlistat and its application to drug quality control studies.
    Souri E; Jalalizadeh H; Kebriaee-Zadeh A; Zadehvakili B
    Chem Pharm Bull (Tokyo); 2007 Feb; 55(2):251-4. PubMed ID: 17268098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stability-indicating high performance liquid chromatographic assay for the determination of orlistat in capsules.
    Mohammadi A; Haririan I; Rezanour N; Ghiasi L; Walker RB
    J Chromatogr A; 2006 May; 1116(1-2):153-7. PubMed ID: 16603170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical quality of nine generic orlistat products compared with Xenical(r).
    Taylor PW; Arnet I; Fischer A; Simpson IN
    Obes Facts; 2010 Aug; 3(4):231-7. PubMed ID: 20823686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Measurement of Lipase Inhibition by Orlistat Using a Dissolution Linked
    Lewis DR; Liu DJ
    Clin Pharmacol Biopharm; 2012; 1():. PubMed ID: 25419492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory kinetics and mechanism of pentacyclic triterpenoid from endophytic Colletotrichum gigasporum against pancreatic lipase.
    Patil R; Patil S; Maheshwari V; Patil M
    Int J Biol Macromol; 2021 Apr; 175():270-280. PubMed ID: 33561462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro anti-obesity activity by pancreatic lipase inhibition - Simple HPLC approach using EVOO as natural substrate.
    Blasi F; Ianni F; Mangiapelo L; Pinna N; Cossignani L
    J Sci Food Agric; 2023 Apr; 103(6):2786-2793. PubMed ID: 36583522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients.
    Zhi J; Mulligan TE; Hauptman JB
    J Clin Pharmacol; 1999 Jan; 39(1):41-6. PubMed ID: 9987699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine.
    Sternby B; Hartmann D; Borgström B; Nilsson A
    Clin Nutr; 2002 Oct; 21(5):395-402. PubMed ID: 12381337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers.
    Shepard TY; Jensen DR; Blotner S; Zhi J; Guerciolini R; Pace D; Eckel RH
    Int J Obes Relat Metab Disord; 2000 Feb; 24(2):187-94. PubMed ID: 10702769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry.
    Schneider A; Wessjohann LA
    J Pharm Biomed Anal; 2010 Nov; 53(3):767-72. PubMed ID: 20570457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kojic acid repurposing as a pancreatic lipase inhibitor and the optimization of its production from a local Aspergillus oryzae soil isolate.
    El-Korany SM; Helmy OM; El-Halawany AM; Ragab YE; Zedan HH
    BMC Biotechnol; 2020 Oct; 20(1):52. PubMed ID: 33008398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARγ as a sensor of lipase activity and a target for the lipase inhibitor orlistat.
    Martin H; McGhie TK; Bentley-Hewitt K; Christeller J
    Lipids Health Dis; 2013 Apr; 12():48. PubMed ID: 23566279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2-methyleneoxetane analog of orlistat demonstrating inhibition of porcine pancreatic lipase.
    Dollinger LM; Howell AR
    Bioorg Med Chem Lett; 1998 Apr; 8(8):977-8. PubMed ID: 9871523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition.
    Dolenc A; Govedarica B; Dreu R; Kocbek P; Srcic S; Kristl J
    Int J Pharm; 2010 Aug; 396(1-2):149-55. PubMed ID: 20540997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample Size Determination and Study Design Impact on Dose-Scale Pharmacodynamic Bioequivalence: a Case Study Using Orlistat.
    Xu L; Li S; Wu W; Cheng Z; Xie F
    AAPS J; 2024 Jul; 26(4):77. PubMed ID: 38960976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.